Yakult Honsha, 4SC to tackle liver cancer in Japanese patients
By Dan Poppy
Thursday, May 8, 2014
Japanese firm Yakult Honsha Co. Ltd. completed phase I trials for resminostat licensed from German firm 4SC AG in solid tumors, as the partners hope to move forward with the target indication of hepatocellular carcinoma (HCC) in Japan, where liver cancer is one of the largest causes of cancer-related death.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.